An independent, multi-center analysis of the post-approval utilization and efficacy of pacritinib and momelotinib in patients with myelofibrosis
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-5600
Abstract: Introduction JAK inhibition is the basis of treatment for most patients (pts) with myelofibrosis (MF). Early JAK inhibitors (ruxolitinib (RUX) and fedratinib) result in myelosuppression that often exacerbates disease-related anemia and thrombocytopenia. The FDA-approval of… read more here.
Keywords: mom; mom treated; pac treated; treated pts ... See more keywords